Summary & Overview
CPT 11621: Excision of Malignant Skin Lesion, 0.6–1.0 cm, Sensitive Areas
CPT code 11621 represents the excision of a malignant skin lesion, including margins, from sensitive anatomical areas such as the scalp, neck, hands, feet, or genitalia, with a lesion diameter between 0.6 and 1.0 cm. This procedure is a critical component of dermatologic surgical care, addressing skin cancers and ensuring comprehensive removal to reduce recurrence risk. Nationally, this code is widely recognized and reimbursed by major payers including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare.
This publication provides an in-depth overview of CPT 11621, covering clinical context, payer coverage, and policy benchmarks. Readers will gain insight into the procedure's role in skin cancer management, typical site of service, and its importance in dermatology practice. The analysis includes updates on payer policies, utilization trends, and relevant clinical guidelines, equipping stakeholders with essential information for understanding reimbursement and compliance. The summary also highlights related codes and modifiers commonly used in conjunction with CPT 11621, offering a comprehensive perspective for healthcare professionals, billing specialists, and policy analysts.
CPT Code Overview
CPT 11621 is used to report the excision of a malignant lesion, including margins, from the scalp, neck, hands, feet, or genitalia, where the lesion diameter measures between 0.6 and 1.0 cm. This procedure falls under the category of dermatology and involves surgical procedures on the integumentary system. The typical site of service for this procedure is the office setting (Place of Service 11), where dermatologists perform excisions to remove cancerous skin lesions and ensure clear margins for optimal patient outcomes.
Clinical & Coding Specifications
Clinical Context
A patient presents to a dermatology office with a suspicious skin lesion on the scalp, neck, hands, feet, or genitalia. The lesion has been clinically or histologically diagnosed as malignant, such as basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ. The lesion measures between 0.6 and 1.0 cm in diameter. The dermatologist performs a surgical excision of the lesion, ensuring removal of the lesion with appropriate margins. The procedure is typically performed in an office setting, and the excised tissue is sent for pathological evaluation to confirm complete removal and diagnosis.
Coding Specifications
-
Modifier
59: Used to indicate a distinct procedural service, such as when multiple lesions are excised in separate anatomical locations or during separate encounters. -
Modifier
51: Used when multiple procedures are performed during the same session, such as excision of more than one lesion.
| Modifier Code | Description |
|---|---|
59 | Distinct Procedural Service |
51 | Multiple Procedures |
- Provider Taxonomy:
| Taxonomy Code | Specialty |
|---|---|
208800000X | Dermatology |
Dermatology specialists are typically responsible for performing this procedure.
Related Diagnoses
-
C44.311: Basal cell carcinoma of skin of nose- Indicates a malignant basal cell carcinoma located on the nose, relevant for excision procedures in this area.
-
C44.321: Squamous cell carcinoma of skin of nose- Represents a malignant squamous cell carcinoma on the nose, requiring excision as described by the CPT code.
-
C44.41: Basal cell carcinoma of skin of scalp and neck- Refers to basal cell carcinoma on the scalp or neck, directly applicable to the excision procedure.
-
C44.42: Squamous cell carcinoma of skin of scalp and neck- Indicates squamous cell carcinoma on the scalp or neck, relevant for excision in these regions.
-
D04.0: Carcinoma in situ of skin of lip- Represents a non-invasive carcinoma in situ on the lip, which may require excision to prevent progression.
Related CPT Codes
-
11620: Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less- Used for excision of smaller malignant lesions (≤0.5 cm) in the same anatomical regions as
11621. May be used when the lesion is smaller than 0.6 cm.
- Used for excision of smaller malignant lesions (≤0.5 cm) in the same anatomical regions as
-
11622: Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; lesion diameter 1.1 to 2.0 cm- Used for excision of larger malignant lesions (1.1–2.0 cm) in the same anatomical regions as
11621. May be used when the lesion is larger than 1.0 cm.
- Used for excision of larger malignant lesions (1.1–2.0 cm) in the same anatomical regions as
These codes are alternatives to 11621 based on lesion size. When multiple lesions of different sizes are excised, these codes may be used together with appropriate modifiers.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 11621 is $236.53 for Medicare, while the BUCA (average commercial) mean rate is $243.86. Commercial payers such as UnitedHealth Group and Cigna have notably higher mean rates, at $340.41 and $306.91 respectively, compared to both Medicare and BUCA.
Rate dispersion varies significantly across payers. Medicare exhibits the tightest range, with a difference of $25.00 between the 75th and 25th percentiles, indicating relatively consistent reimbursement. In contrast, UnitedHealth Group shows the widest dispersion, with a $204.67 difference between the 75th and 25th percentiles, reflecting greater variability in rates. The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.